TL;DR: POC vs Central Laboratory Testing
- Central labs batch specimens under trained technologists; POC returns results at the bedside in minutes to hours (Kost, 2023; Kankaanpää et al., 2018)
- POC wins on turnaround; central labs usually win on per-test cost and analytical control at scale (Price, 2001; Larsson et al., 2015)
- Analytical agreement is often acceptable for selected analytes, but methods are not interchangeable; troponin, INR, and creatinine may show bias across platforms (ASCLS, 2019)
- Patient-outcome evidence is thinner than analytical comparisons; process redesign matters as much as device speed (Goyder et al., 2020)
- Choose POC when delay would change management in the same encounter; choose the lab when precision, batch QC, or complex panels dominate (Engel et al., 2015; Nichols et al., 2020)
From the Motif team: Last reviewed June 2026. POC-vs-lab decisions fail when teams cite central-laboratory PMIDs for a bedside cartridge. Motif tags literature by study setting and specimen matrix so validation plans match the environment where the test will run. Start with our point-of-care diagnostics overview for definitions and device types.
Clinicians rarely choose between point-of-care testing and central laboratory testing in the abstract. They choose between waiting two hours for a send-out troponin panel and having a cartridge result in twelve minutes while the patient is still on the gurney. The trade-off is speed against control: who runs the assay, where quality is enforced, and whether the result will actually change what happens before discharge.
That trade-off is not uniform across analytes. A glucose meter and a mass-spectrometry vitamin D send-out sit at opposite ends of complexity, yet both appear in "POC vs lab" debates. This article compares the two models on turnaround, accuracy, cost, and clinical fit, with sources that separate analytical agreement from proven outcome benefit.
How Central Laboratory Testing Works
Traditional laboratory medicine routes specimens through collection, transport, accessioning, batch analysis, verification, and result reporting. Trained clinical laboratory scientists operate under standardized quality systems: internal QC, external proficiency testing, instrument maintenance logs, and documented corrective action when controls fail (Kost, 2023).1
Consolidation has pushed more volume into fewer high-throughput sites. That scale lowers unit cost and stabilizes precision, but adds pre-analytical delay. A chemistry panel drawn at 14:10 may not hit the analyzer until the next transport cycle; results return when the patient has already left or is boarding in the ED. Plebani and Laposata (2011) described the "brain-to-brain loop" from clinician question to laboratory answer; every handoff lengthens it.2
How Point-of-Care Testing Differs
POCT collapses parts of that loop. Samples are tested at or near the patient (ED, ICU, clinic, pharmacy, ambulance, or home), often by nurses, physicians, or patients rather than laboratory staff (Price, 2001). DOI: 10.1136/bmj.322.7297.1285. Turnaround for many devices is 10–30 minutes versus 60+ minutes for central-lab chemistry in busy hospitals (Kankaanpää et al., 2018).3
The definitional bar is clinical, not just temporal. Engel et al. (2015) argue that any POC program should produce an actionable management decision (treatment, referral, or confirmatory testing) within the same encounter.4 A fast result that nobody acts on is still a delayed result from the patient's perspective.
Decision rule of thumb: POC earns its place when the allowable decision time is shorter than central-lab turnaround for that analyte in your institution, and when acting on the result is built into the pathway.
Turnaround Time: Where POC Wins Clearly
ED studies consistently show shorter time-to-result with POC. Kankaanpää et al. (2018) compared a comprehensive POC panel (blood gases, chemistry, CBC, CRP) with central-laboratory processing in Finnish emergency patients. Median wait for blood sampling was 19 minutes shorter with POC; among patients discharged home, length of stay fell by 55 minutes without imaging and 82 minutes when imaging was required.3
A cluster-randomized French ED study (n = 20,923 analyzed) reported mean time-to-result of 28 vs 79 minutes with extended POC vs central lab, a 51-minute reduction, though overall ED length of stay did not reach statistical significance for the full population (Hausfater et al., 2020).5 Faster results do not automatically shorten boarding if bottlenecks sit in imaging, consults, or bed availability.
Kankaanpää et al. (2016) earlier showed that introducing POC plus an early-assessment workflow cut ambulatory ED length of stay by 46 minutes over three phases.6 Process redesign amplified device speed. POC alone, dropped into an unchanged workflow, often underdelivers.
Analytical Accuracy: Agreement Is Not Identity
Meta-analyses and method-comparison studies report acceptable correlation for many POC immunoassays (troponin, BNP, CRP among them) when operators follow manufacturer protocols (Pecoraro et al., 2017).7 Acceptable correlation is not interchangeability.
ASCLS patient-safety guidance warns that results from point-of-care and clinical-laboratory analyzers may disagree even when reference intervals look identical. Documented bias-prone examples include hemoglobin, hematocrit, creatinine, PT/INR, activated clotting time, troponin, and quantitative β-hCG. Switching a hospitalized patient from a clinic POC creatinine to a hospital core-lab method without re-baselining can misclassify acute kidney injury.
Central laboratories detect interference (hemolysis, icterus, lipemia) more systematically than many whole-blood POC devices. Operator-dependent steps (inadequate mixing, wrong cartridge lot, expired strip) add variance that batch QC in a core lab would flag before release (Price et al., 2018).8
Cost: Per-Test vs System Cost
On a unit-cost basis, POC is usually more expensive. Single-use cartridges, decentralized inventory, and duplicated device fleets lack central-lab economies of scale (Larsson et al., 2015).9 POCTA and industry white papers note higher consumable cost per test offset only when downstream savings (fewer admissions, shorter stays, reduced follow-up visits) are modeled honestly.
EFLM authors emphasize evaluating total pathway cost, not reagent price alone (Trenti et al., 2021).10 A €12 POC CRP test that prevents a €200 unnecessary antibiotic course and a return visit can be cost-effective; the same test ordered reflexively on every URI without a stewardship rule burns budget.
Florkowski et al. (2017) reviewed evidence-based laboratory medicine for POCT and found analytical performance studies far outnumber rigorous cost-effectiveness or outcome trials.11 Budget committees should demand pathway models, not brochure arithmetic.
Quality Systems and Oversight
CLIA in the United States classifies tests by complexity (waived, moderate, high) with corresponding personnel and QC requirements. CAP and ISO 22870 expect laboratory oversight of decentralized testing: competency assessment, connectivity, EQC, and incident review (Nichols et al., 2020).12 ASCLS position statements require qualified technical consultants for POC programs regardless of setting.
POC multiplies sites of failure. One core lab services one QC program; forty ED glucose meters need forty operator competency files. Connectivity (POCT1-A, LIS integration) is not optional at scale; orphaned results on a printer tray do not improve care.
When to Choose Point-of-Care Testing
- Time-critical pathways: chest pain serial troponin, sepsis lactate, anticoagulation INR adjustment, hypoglycemia treatment
- Same-visit disposition: CRP-guided antibiotic decisions in primary care, rapid strep or influenza in urgent care
- No on-site laboratory: rural clinics, ambulances, disaster response, retail pharmacy models
- Loss-to-follow-up risk: STI, TB, and HIV programs where patients do not return for batched NAAT results (Pai et al., 2012).13
- Process-integrated panels: ED early-assessment models that pair POC with dedicated nursing workflows (Kankaanpää et al., 2016)
For infectious-disease molecular decisions at the bedside, see our blog on molecular point-of-care diagnostics.
When Central Laboratory Testing Is Preferable
- High-complexity or esoteric testing: mass spectrometry, karyotype, NGS panels, specialized autoantibody profiles
- Screening without immediate intervention: tests where same-day action is not planned, though define "screening" carefully per intended use
- Maximum analytical precision: reference-method traceability, interference detection, wide dynamic range
- Batch efficiency: high-volume routine chemistry and hematology at lowest unit cost
- Longitudinal monitoring on one method: oncology markers, transplant immunosuppression levels where method switching biases trends
Central lab and POC are complements in consolidated health systems, not rivals (Trenti et al., 2021). Laboratory medicine departments increasingly govern POC menus, vendor selection, and quality while decentralizing execution.
Outcome Evidence: The Missing Layer
Goyder et al. (2020) meta-analyzed POC panel tests in ambulatory care and found heterogeneous effects on referrals, prescribing, and satisfaction, not a universal outcome win.14 Pecoraro et al. (2017) systematically reviewed immunoassay POC studies and noted frequent gaps in patient-centered endpoints.7
The EFLM Test Evaluation Working Group advocates outcome-linked assessment: which management decision changes, with what health effect, compared with the prior laboratory test (Trenti et al., 2021). GRADE-style evidence grading fits POC adoption decisions better than sensitivity tables alone.
Practical Comparison Table
Use this as a planning aid, not a substitute for local validation.
- Turnaround: POC: minutes to ~1 hour; Central lab: often 1–24+ hours depending on test and site
- Unit cost: POC: typically higher; Central lab: typically lower at volume
- Analytical control: POC: distributed, operator-dependent; Central lab: centralized QC/proficiency
- Method interchangeability: POC: often limited; Central lab: reference traceability
- Best evidence base: POC: turnaround and stewardship; Central lab: esoteric and high-precision assays
Literature Review Before Method Selection
Teams scoping a POC adoption or cartridge program should separate evidence types before writing clinical claims:
- Analytical method-comparison studies (POC vs reference) for your matrix
- Pathway studies measuring time-to-treatment or disposition
- Outcome trials (mortality, admission rates, antibiotic days) where they exist
- Health-economic models with transparent assumptions
Motif extracts biomarker and diagnostic associations from PubMed and PMC with PMIDs, filters by study setting, and exports cited tables for IVDR/FDA briefing sections, so POC business cases cite bedside evidence, not misapplied central-lab pivotal trials.
Frequently Asked Questions
Is point-of-care testing less accurate than laboratory testing?
Not always. Many POC devices show strong agreement with reference methods for specific analytes when maintained and operated correctly. POC can be less precise for some tests, more vulnerable to operator and pre-analytical error, and non-interchangeable with central-lab methods for troponin, INR, creatinine, and others. Accuracy is device- and setting-specific (Price et al., 2018; ASCLS, 2019).
Why is POC more expensive per test?
Cartridge-based decentralization sacrifices batch economies of scale. Each test carries device amortization, single-use reagents, and distributed quality-program overhead. Economic justification depends on avoided downstream costs (admissions, imaging, follow-up visits), not reagent price alone (Larsson et al., 2015; Trenti et al., 2021).
Does POC reduce emergency department length of stay?
Sometimes. Finnish and other ED studies show shorter time-to-result and discharge in selected patient groups when POC is workflow-integrated. Large randomized studies show major TTR gains with smaller or non-significant LOS effects for the whole ED population. Process bottlenecks beyond the laboratory often dominate (Kankaanpää et al., 2018; Hausfater et al., 2020).
Can I use the same cutoff for POC and central-lab troponin?
Generally no without local validation. Assay generation, specimen type, and 99th percentile URLs differ. Thygesen et al. (2018) MI criteria assume validated high-sensitivity pathways; cartridge POC must demonstrate equivalent detection and delta performance in the matrix collected at bedside.15
Who oversees point-of-care testing quality?
In accredited U.S. hospitals, the clinical laboratory typically directs the POC program under CLIA and CAP requirements: competency, QC, proficiency testing, and device connectivity. ISO 22870 applies internationally for near-patient testing competence (Nichols et al., 2020; Kost, 2023).
How should researchers compare POC and lab literature?
Tag each PMID with setting (bedside vs central), specimen matrix, device name, and endpoint type (analytical vs outcome). Motif automates extraction and GRADE-adapted scoring so meta-summaries do not pool incompatible studies.
References
- Kost, G.J. (2023). Point-of-Care Testing. In: StatPearls. PMID: 37276307
- Plebani, M., & Laposata, M. (2011). Brain-to-brain loop for laboratory testing. Am J Clin Pathol, 136(6), 829-833. PMID: 22095366
- Kankaanpää, M., et al. (2018). Comprehensive POC panel vs central lab in ED. BMC Emerg Med, 18, 43. PMID: 30453888
- Engel, N., et al. (2015). Point-of-care testing in India: missed opportunities. BMC Health Serv Res, 15, 550. PMID: 26652014
- Hausfater, P., et al. (2020). Impact of POCT on ED length of stay. Acad Emerg Med, 27(8), 730-741. PMID: 32621374
- Kankaanpää, M., et al. (2016). POCT and early assessment reduce ED LOS. Scand J Trauma Resusc Emerg Med, 24, 125. PMID: 27756354
- Pecoraro, V., et al. (2017). Systematic evaluation of immunoassay POCT impact. Ann Clin Biochem, 54(4), 420-431. PMID: 28135840
- Price, C.P., et al. (2018). Improving quality of point-of-care testing. Fam Pract, 35(4), 358-364. PMID: 29253125
- Larsson, A., et al. (2015). State of point-of-care testing: European perspective. Ups J Med Sci, 120(1), 1-10. PMID: 25622619
- Trenti, T., et al. (2021). Synergy between POCT and laboratory consolidations. EJIFCC, 32(3), 328-336. PMID: 34819822
- Florkowski, C., et al. (2017). POCT and evidence-based laboratory medicine. Crit Rev Clin Lab Sci, 54(7-8), 471-494. PMID: 29169287
- Nichols, J.H., et al. (2020). AACC guidance on management of POCT. J Appl Lab Med, 5(4), 762-787. PMID: 32496555
- Pai, N.P., et al. (2012). POC testing for infectious diseases in LMICs. PLoS Med, 9(4), e1001306. PMID: 23330251
- Goyder, C., et al. (2020). Impact of POC panel tests in ambulatory care. BMJ Open, 10(2), e032132. PMID: 32111610
- Thygesen, K., et al. (2018). Fourth universal definition of MI. Circulation, 138(20), e618-e651. PMID: 30571511
- American Society for Clinical Laboratory Science. (2019). Point of care testing: use and limitations for providers.
- Price, C.P. (2001). Point of care testing. BMJ, 322(7297), 1285-1288. DOI: 10.1136/bmj.322.7297.1285
